LifeLink Tissue Bank Response to COVID-19 Outbreak:

From the initial onset of the COVID-19 outbreak overseas (and the initial cases in the U.S), the LifeLink Tissue Bank has closely monitored and implemented all guidance and recommendations from the FDA and AATB. The first guidance was issued January 31, 2020, at which time LifeLink started screening potential donors for risk factors associated with the disease. Since that date, we have followed and implemented all additional industry guidance in order to assure the safety of our staff and our processed tissue, and LifeLink implemented an additional layer of safety to test for COVID-19.

LifeLink Tissue Bank will continue to observe FDA, AATB and CDC guidelines as we continue to process quality allograft tissue for our many customers and partners. The safety of our employees, all healthcare workers and allograft recipients will remain our number one priority.

LifeLink Tissue Bank Management